IndiaLife Style

Glenmark is the first company to launch in India

a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance

This Fixed-Dose Combination (FDC) of Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin
(500mg/1000mg) SR under the brand name Zita®-PioMet.

The novel triple FDC will help improve glycemic control among adults with High HbA1c 1 and high
insulin resistance, those whose diabetes is uncontrolled by metformin alone; and those who
require the addition of Teneligliptin and Pioglitazone as separate drugs; thus improving
adherence with single pill. 

Priced at Rs. 14.90 per day, it will reduce the daily cost of therapy by 40%, making it more
affordable to the masses.
Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global
pharmaceutical company has launched the first triple fixed-dose combination Teneligliptin with
Pioglitazone and Metformin in India. Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor).

This FDC has been launched under the brand name Zita®-PioMet, and contains
Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR)
formulation. This offers patients with Type 2 diabetes the convenience of once daily dosing to improve
their glycemic control and achieve the targeted HbA1c within 24 weeks. 

On occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark
Pharmaceuticals Ltd., said, “Type 2 diabetes patients in India often face issues of beta cell
dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is
38% compared to the global incidence of 15% ii . Being a leader in diabetes therapy in the country, we
are proud to introduce Zita®-PioMet, India’s first triple fixed dose combination for high insulin-
resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the
glycemic control among adult patients with high HbA1c.”

Glenmark’s Leadership in the Diabetes Segment
Glenmark has a strong legacy of bringing in new, effective and affordable treatment options for
diabetic patients, especially the ones with uncontrolled Type 2 diabetes. In 2015, Glenmark was the
first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus® and Ziten®), followed by a FDC of
Teneligliptin + Metformin

(Zita-Met Plus® and Ziten-M®). Glenmark later launched Remogliflozin (Remo® and Remozen™), a
novel SGLT‐2 inhibitor in 2019 and subsequently, its combinations with Metformin and Vildagliptin
(Remo-V®, Remozen™-V, Remo MV® and Remozen™ MV). Earlier in 2022, Glenmark also launched
Sitagliptin (Sitazit®) and its FDCs, followed by Lobeglitazone (LOBG®) and FDCs of Teneligliptin including
its combinations with Pioglitazone (Zita Pio™) and Dapagliflozin (Zita-D™).

Diabetes in India
According to IQVIA™ sales data for the 12‐month period ending November 2022, the market for oral
anti‐diabetic drugs in India is estimated to be Rs. 11,877 Cr. with an annual growth of 6.3% against the
corresponding period last year (MAT November 2021). As per the International Diabetes Federation
(IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77% of which
would have uncontrolled diabetes.

About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven global
pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on
the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world‐class
manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is
ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by
Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the
off‐patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics
Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the
world’s most respected and widely accepted sustainability benchmarks, under the category of
emerging markets (2021) for the fourth consecutive year. For more information, visit, LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma).

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button